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4-hydroxy-3-methoxycinnamic acid regulates
orexigenic peptides and hepatic glucose homeostasis
through phosphorylation of FoxO1
Ann W Kinyua1, Chang Mann Ko1, Khanh V Doan1,3, Dong Joo Yang1, My Khanh Q Huynh1,
Sang Hyun Moh2, Yun-Hee Choi2 and Ki Woo Kim1,4
4-hydroxy-3-methoxycinnamic acid (ferulic acid, FA) is known to have numerous beneﬁcial health effects, including anti-obesity
and anti-hyperglycemic properties. However, the molecular networks that modulate the beneﬁcial FA-induced metabolic effects
have not been well elucidated. In this study, we explored the molecular mechanisms mediating the beneﬁcial metabolic effects
of FA. In mice, FA protected against high-fat diet-induced weight gain, reduced food intake and exhibited an overall improved
metabolic phenotype. The food intake suppression by FA was accompanied by a speciﬁc reduction in hypothalamic orexigenic
neuropeptides, including agouti-related protein and neuropeptide Y, with no signiﬁcant changes in the anorexigenic peptides pro-
opiomelanocortin and cocaine and amphetamine-regulated transcript. FA treatment also inhibited fat accumulation in the liver
and white adipose tissue and suppressed the expression of gluconeogenic genes, including phosphoenolpyruvate carboxylase and
glucose-6-phosphatase. Furthermore, we show that FA phosphorylated and inactivated the transcription factor FoxO1, which
positively regulates the expression of gluconeogenic and orexigenic genes, providing evidence that FA might exert its beneﬁcial
metabolic effects through inhibition of FoxO1 function in the periphery and the hypothalamus.
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INTRODUCTION
Obesity is a chronic disorder of energy homeostasis that is
associated with numerous health complications, including type
II diabetes.1 Dysregulation of whole body energy metabolism
resulting from an imbalance in energy consumption and energy
expenditure is the primary cause of obesity development.2 The
central nervous system (CNS), particularly the hypothalamus,
has an important role in maintaining whole-body energy
homeostasis by integrating nutritional signals from peripheral
organs and therefore regulates feeding and energy
expenditure.3,4 The arcuate nucleus of the hypothalamus
consists of two distinct neuronal populations that regulate
not only food intake but also energy expenditure and body
weight. The orexigenic agouti-related protein (AgRP)- and
neuropeptide Y (NPY)-expressing neurons stimulate feeding,
whereas the anorexigenic pro-opiomelanocortin (POMC)- and
cocaine and amphetamine-regulated transcript (CART)-
expressing neurons inhibit food intake and increase energy
expenditure.5–9
The transcription factor FoxO1 is a downstream target of the
PI3K/AKT pathway, which is important for various physiolo-
gical processes including the regulation of energy
homeostasis.10–12 In the hypothalamus, insulin and leptin
converge at the AKT/FoxO1 pathway to regulate the expression
of both orexigenic and anorexigenic genes.13–16 FoxO1 upre-
gulates the expression of AgRP but inhibits POMC expression,
therefore promoting food intake. However, leptin and insulin
antagonize the effects of FoxO1 by phosphorylating and
inactivating FoxO1 to suppress food intake.17–19 In peripheral
tissues, FoxO1 regulates the expression of key gluconeogenic
genes, phosphoenolpyruvate carboxylase (PEPCK) and glucose-
6-phosphatase (G6P),20 demonstrating the important role of
FoxO1 in the regulation of glucose homeostasis.
4-hydroxy-3-methoxycinnamic acid (ferulic acid, FA) is
found in grains, fruits and even in marine algae.21,22 Previous
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studies have demonstrated the various beneﬁcial metabolic
effects of FA, including reduced serum and hepatic lipid
accumulation in diabetic rats, protection against lipid induced
insulin resistance23,24 and improved glucose tolerance and
insulin sensitivity.25–27 Whereas most studies on the anti-
diabetic and anti-hyperglycemic activities of FA have focused
on peripheral tissues, the molecular networks mediating these
effects have not been clearly elucidated. Moreover, the CNS-
mediated metabolic roles of FA have yet to be explored.
In this study, we observed that FA has a protective role
against the development of high-fat diet (HFD)-induced
obesity by reducing food intake, and improving glucose
metabolism and insulin sensitivity. FA also suppressed lipid
accumulation in the liver and white adipose tissue. The
beneﬁcial effects of FA were accompanied by the inhibition
of gluconeogenic genes, PEPCK and G6P, in the liver and the
suppression of orexigenic genes, AgRP and NPY, in the
hypothalamus. Interestingly, we found that FA phosphorylated
and led to the nuclear exclusion of FoxO1, a known transcrip-
tion factor that is an important regulator of the expression of
gluconeogenic and orexigenic genes. Therefore, our data
suggest that the beneﬁcial metabolic effects of FA might be a
result of the combined effects of FA on the inhibition of
hepatic glucose production and the suppression of food intake
and that these effects may be exerted through suppression of
FoxO1 activity.
MATERIALS AND METHODS
Animal experiments
All animal experiments were approved by the Institutional Animal
Care and Use Committee of Yonsei University, Wonju College of
Medicine. C57BL/6 male mice were housed in a controlled environ-
ment with a 12 h dark/light cycle at a room temperature of 22–24 °C.
Mice were divided into three experimental groups. The ﬁrst group
(n= 4) was maintained on normal chow diet purchased from Zeigler
Bros., Inc. (Cat. No. NIH-31M Auto, Gardners, PA, USA). The second
group (n= 5) was fed a HFD obtained from Research Diets Inc. (Cat.
No. D12429, New Brunswick, NJ, USA) for 12 weeks. The third group
(n= 6) was fed a HFD together with an intraperitoneal injection of
10 mg kg− 1 FA28 every other day for 12 weeks. Food intake was
monitored for 3 consecutive days at 8am and 5pm on 14-week-old
mice. FA was purchased from Sigma (Cat. No 128708, St. Louis, MO,
USA) and dissolved in 1% Tween 80, 1% DMSO and 98% saline. The
control groups (normal chow and high fat diet) were injected with
vehicle.
Glucose (GTT), pyruvate (PTT) and insulin (ITT) tolerance
tests
For the GTT and PTT, mice were fasted overnight for 16–18 h and
provided with water ad libitum. The following morning, mice were
housed in individual cages and allowed to acclimatize for 2 h followed
by intraperitoneal injection of 1.2 g kg− 1 glucose (Sigma) for GTT and
2 g kg−1 sodium pyruvate (Sigma) for PTT. GTT was performed on
15-week-old mice; the NC (normal chow)-fed cohort (n= 4) had a
body weight of 27.6± 0.3 g, the HFD-fed cohort (n= 5) had a body
weight of 41.7± 1.2 g, and the HFD+FA cohort (n= 6) had a body
weight of 35.6± 0.6 g. PTT was performed on 17-week-old mice; the
NC-fed cohort (n= 4) had a body weight of 29.7± 0.5 g, the HFD
cohort (n= 4) had a body weight of 48.2± 1.4 g and the HFD+FA
(n= 6) had a body weight of 42.4± 0.8 g. For ITT, the mice were
fasted and stabilized for 2 h in individual cages with free access to
water. Insulin, 0.9 U kg− 1, (Eli Lilly and Company, IN, USA) was
administered intraperitoneally. ITT was performed on 16-week-old
mice; the NC-fed cohort (n= 4) had a body weight of 29.6± 0.2 g, the
HFD cohort (n= 5) had a body weight of 48.9± 0.6 g and the HFD
+FA cohort (n= 6) had a body weight of 40.9± 0.7 g. Blood samples
were obtained from a tail nick and the blood glucose levels were
measured at 0, 20, 40, 60, 90, 120 and 150 min using a commercial
glucometer (Bayer HealthCare, Mishawaka, IN, USA).
Hormone measurement
Blood serum was collected at 10:00 am from 18 week old mice and the
insulin and leptin levels were measured using an ELISA kit obtained
from the Morinaga Institute of Biological Science (Yokohama, Japan)
following the manufacturer’s protocol.
Cell culture
The hypothalamic N1,29 hepatic HepG230 and human embryonic
kidney (HEK293) cells10 were cultured in Dulbecco's Modiﬁed Eagle
Medium supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin. The cells were maintained at 37 °C and 5%
CO2.
RNA isolation and real-time quantitative PCR
RNA was isolated from cells and tissue samples using Trizol (Life
Technologies, Carlsbad, CA, USA), following the manufacturer’s
protocol. One microgram of total RNA was used to synthesize cDNA
using the high capacity cDNA reverse transcription kit (Applied
Biosystems, Foster City, CA, USA). Q-PCR was performed using the
SYBR Green PCR master mix from Applied Biosystems. The mouse
Q-PCR primer sequences are listed below: PEPCK; 5′-CGCAAG
CTGAAGAAATATGACAA-3′ and 5′-TCGATCCTGGCCACATC
TC-3′, G6P; 5′-TGGGCAAAATGGCAAGGA-3′ and 5′-TCTGCCCCA
GGAATCAAAAAT-3′, NPY; 5′-CTACTCCGCTCTGCGACACT-3′
and 5′-AGTGTCTCAGGGCTGGATCT-3′, AgRP; 5′-CGGCCAC
GAACCTCTGTAG-3′ and 5′-CTCATCCCCTGCCTTTGC-3′, POMC;
5′-CAGGTCCTGGAGTCCGAC-3′ and 5′-CATGAAGCCACCGT
AACG-3′, CART; 5′-AGAAGAAGTACGGCCAAGTC-3′ and 5′-
GGACAGTCACACAGCTTCC-3′. The human Q-PCR primers
sequences are as follows, PEPCK; 5′-CAGGCGGCTGAAGAAGTA
TGA-3′ and 5′-AACCGTCTTGCTTTCGATC-3′, G6P; 5′-GCCACAT
CCACAGCATCTATAA-3′ and 5′-CCAGAGTCCACAGGAGGTCT
AC-3′.
Western blot
Protein was isolated from cells and tissue samples using radio-
immunoprecipitation assay buffer enriched with protease and phos-
phatase inhibitors (Roche, Basel, Switzerland). Equal amounts of
protein were loaded and separated on sodium dodecyl sulphate-
acrylamide gels and then incubated with speciﬁc antibodies. The
following primary antibodies were used: pAKT (4060S), AKT (2967S),
pFOXO1 (9461S), FOXO1 (2880S), Lamin A/C (2032S) and PEPCK
(12940S) from Cell Signaling Technology (Danvers, MA, USA).
GAPDH (SC-25778) was from Santa Cruz Biotechnology (Santa Cruz,
CA, USA) and G6P (ab83690) was from Abcam (Cambridge, UK).
The protein levels were detected using Pierce ECL western blotting
substrate (Waltham, MA, USA) following the standard western blot
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procedure, as described previously.10 Images were captured with a
UVP Bio-Spectrum 600 imaging system (Ultra-Violet Products Ltd.
Cambridge, UK).
Cell fractionation
HEK 293 cells were harvested and the cell membranes lysed using ice-
cold buffer A containing 10 mM 4-(2-hydroxyethyl)-1-piperazineetha-
nesulfonic acid (pH 7.9), 10 mM KCL, 0.1 mM EDTA (pH 8.0), 0.1 mM
EGTA (pH 8.0), 1 mM DTT, and protease and phosphates inhibitors.
10% Triton X-100 was added to the samples followed by 1 min
centrifugation. The cytoplasmic supernatant was then collected. The
pellet was then lysed with ice cold buffer C containing 20 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.9),
400 mM NaCl, 1 mM EDTA (pH 8.0), 1 mM EGTA ( pH 8.0), 1 mM
DTT and protease and phosphatase inhibitors. The supernatant
containing the nuclear extract was collected. Protein levels in the
cytoplasmic and nuclear extracts were detected following the standard
western blot procedure. GAPDH and Lamin A were used as internal
controls for the cytoplasmic and nuclear extracts, respectively.
FoxO1 localization assay
FoxO1 localization was assayed by transfecting HEK 293 cells with
FoxO1-GFP using Lipofectamine 2000 (Thermo Fisher Scientiﬁc,
Waltham, MA, USA), followed by 6 h FA treatment. The cells were
ﬁxed in 4% paraformaldehyde for 10 min and washed three times with
phosphate-buffered salinePBS. Slides were mounted using VECTA-
SHIELD mounting medium with DAPI (Vector Laboratories, Inc.
Burlingame, CA, USA) and visualized using the Olympus BX51
ﬂuorescence microscope (Olympus Corporation, Tokyo, Japan).
Luciferase assay
PEPCK and G6P luciferase constructs were kindly provided by Dr
Hueng-Sik Choi, as previously described.31 AgRP, NPY and POMC
luciferase constructs were kindly provided by Dr Min-Seon Kim, as
previously described.19 HEK 293 cells were transfected with speciﬁc
DNAs using Lipofectamine 2000 (Thermo Fisher Scientiﬁc) following
the manufacturer’s protocol, and renilla (100 ng) was co-transfected as
an internal control. Cells were lysed using luciferase lysis buffer
composed of 25 mM Tris phosphate pH 7.8, 2 mM DTT, 2 mM EDTA,
10% glycerol and 1% Triton X-100. The cell lysate samples were
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Figure 1 Improved metabolic proﬁle after FA treatment. Weekly body weight (a), day and night food intake (b), cumulative daily food
intake (c), and blood insulin level (d) in mice fed NC, HFD or HFD+FA. Note that day and night food intake was measured at 8am and
5pm for 3 consecutive days. Glucose tolerance test (GTT) (e) and area under curve (AUC) for the GTT (f). Insulin tolerance test (ITT) (g)
and AUC for the ITT (h). Plasma leptin level (i). Representative images for H&E staining in white adipose tissue (j) and liver (k). The lower
panel indicates a higher magniﬁcation from the upper panel. The number of animals is expressed in parenthesis. The values are mean
± s.e.m. (*Po0.05, Student’s t-test, two-way ANOVA for a, e and g). NC, normal chow. HFD, high-fat diet. FA, 4-hydroxy-3-
methoxycinnamic acid (ferulic acid). Scale bar, 100 μm.
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assayed in triplicate after injection of luciferase and renilla substrates
using the BioTek Synergy TM 2 machine (BioTek Instruments Inc.,
Winooski, VT, USA). The luciferase substrate (pH 8.0) was composed
of 200 mM Tris-HCL, 15 mM MgSO4, 0.1 mM EDTA, 25 mM DTT,
1 mM ATP, 0.2 mM coenzyme A and 200 μM luciferin. The renilla
substrate (pH 5.0) was composed of 1.1 M NaCl, 2.2 mM Na2EDTA,
0.22M KH2PO4 (pH 5.1), 0.44 mg ml
−1 BSA, 1.3 mM sodium azide,
1.43 μM coelenterazine.32 The relative luciferase activity of the FA
treatment was calculated as a ratio of luciferase and renilla activity
normalized to vehicle treatment.
Histological analysis
White adipose tissue and liver samples were ﬁxed in 4% neutral
buffered formalin. The tissue samples were then parafﬁn embedded
and cut into 5 μm slices. The slices were stained with hematoxylin and
eosin (H&E) following the standard H&E procedure. The stained
slides were visualized by a Nikon Digital Camera DXM1200 micro-
scope system (Nikon Corporation, Tokyo, Japan).
Statistical analysis
The data were analyzed using GraphPad Prism 5.0 software. Statistical
comparisons were performed using Student’s t-test or ANOVA, and
results with a P-value o0.05 were considered to be statistically
signiﬁcant. All results are expressed as the mean± s.e.m. as indicated
in the ﬁgure legends.
RESULTS
FA improves metabolic phenotype in HFD-induced obese
mice
To investigate the metabolic effects of FA, male BL6 mice were
divided into three groups. One group was maintained on
normal chow diet, another group on HFD and the third group
was fed HFD plus a 10mg kg− 1 FA intraperitoneal injection
every other day for 12 weeks. The FA-treated mice showed
signiﬁcantly lower body weight gain under HFD compared
with vehicle treated littermates (Figure 1a), indicating that FA
might have protective effects against HFD-induced obesity.
Next, we monitored food consumption to examine whether the
decrease in body weight gain observed in FA-treated mice
resulted from altered food intake. Intriguingly, FA treated mice
exhibited a signiﬁcant decrease in day and night food con-
sumption as well as cumulative daily food intake (Figure 1b
and c). Together with the regulation of body weight, assess-
ment of serum insulin levels showed that the HFD-induced
increase in serum insulin level was signiﬁcantly blunted by FA
treatment, suggesting that FA might improve glucose and
insulin sensitivity (Figure 1d). To further investigate the effect
of FA on glucose and insulin homeostasis, we performed GTT
and ITT. The FA-treated mice exhibited improved glucose
tolerance and increased insulin sensitivity compared with
control littermates (Figure 1e–h). In general, obesity is asso-
ciated with increased leptin levels in the blood as well as the
development of leptin resistance. HFD has also been shown to
contribute to increased plasma leptin levels.33–35 In this study,
we observed that FA markedly reduced the HFD-induced
increase in serum leptin level (Figure 1i) and decreased food
intake (Figure 1b and c), suggesting that FA might be involved
in the regulation of leptin sensitivity. This improved metabolic
phenotype in the FA-treated mice was associated with a marked
reduction in the size and accumulation of lipid droplets in the
white adipose tissue and liver compared with the HFD control
group (Figure 1j and k). Collectively, these data highlight the
beneﬁcial metabolic effects of FA in the protection against
HFD-induced obesity.
Suppression of HFD-induced hepatic glucose production
by FA
Several studies have suggested that improved glucose and
insulin tolerance is associated with the inhibition of hepatic
glucose production.36–38 These, together with the improved
glucose, insulin, and leptin levels in the FA-treated group, led
us to hypothesize that FA might reduce hepatic glucose
production in HFD-induced obese mice. To address this
question, we examined the expression of the rate limiting
enzymes for gluconeogenesis, PEPCK and G6P. The expression
of PEPCK and G6P was signiﬁcantly blunted by FA treatment
and this suppression was comparable with insulin treatment in
HepG2 cells (Figure 2a and b). Luciferase assays also showed a
marked reduction in PEPCK and G6P promoter activity after
FA treatment (Figure 2c and d). Consistent with the in vitro
results, FA markedly blunted the HFD-induced PEPCK and
G6P increase observed in the liver (Figure 2e–h). Finally, we
performed PTT to directly assess the role of FA in hepatic
glucose homeostasis by challenging mice with the gluconeo-
genic precursor, pyruvate. As shown in Figure 2i and j, the FA
treated mice showed signiﬁcantly improved pyruvate tolerance
as evidenced by a signiﬁcant reduction in area under the curve
compared with vehicle-treated HFD-obese littermates. Taken
together, our data suggest that FA improves insulin sensitivity
by reducing hepatic glucose output, possibly by inhibiting the
expression of gluconeogenic genes.
Inactivation of FoxO1 is required for the suppression of
hepatic gluconeogenic genes by FA
FoxO1 is a transcription factor localized in the nucleus in its
active state. However, upon phosphorylation, mainly by AKT,
it is translocated to the cytoplasm where it is inactivated and
eventually degraded. FoxO1 is known to regulate the expres-
sion of PEPCK and G6P in the liver to maintain glucose
homeostasis.39 Given that FA treatment signiﬁcantly increased
the phosphorylation of both FoxO1 and AKT accompanied by
suppression of the HFD-induced expression of PEPCK and
G6P in the liver, we hypothesized that FA exerted its
suppressive effects on PEPCK and G6P by modulating the
activity of FoxO1 (Figure 2e–h). To further investigate this, we
administered FA dose and time dependently and monitored
FoxO1 activity in HepG2 cells. FA treatment induced a
signiﬁcant phosphorylation of AKT and FoxO1 dose and time
dependently, with the highest effect observed by 10 μM FA
treatment (Figure 3a and b and Supplementary Figure 1a
and b). In addition, FA signiﬁcantly suppressed PEPCK and
G6P protein levels in a dose- and time-dependent manner
(Figure 3a and b and Supplementary Figure 1c and d). The
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phosphorylation of FoxO1 by FA facilitated FoxO1 nuclear
exclusion in a manner comparable to insulin-induced FoxO1
translocation (Figure 3c–e). Taken together, these data show
that FA might facilitate the phosphorylation and inactivation of
FoxO1 and thereby suppress the expression of the FoxO1
gluconeogenic targets, PEPCK and G6P.
FA inhibits hypothalamic orexigenic neuropeptides by
FoxO1 inactivation
Another metabolic characteristic observed in the FA-treated
mice was a reduction in calorie intake compared with vehicle-
treated control mice (Figure 1a–c). It is well known that calorie
intake is tightly regulated by a central feeding system in
response to satiety signals generated by the peripheral system.
Following a study reporting that FA is capable of crossing the
blood–brain barrier,40 we hypothesized that FA might be
involved in the modulation of the hypothalamic neuropeptides
that regulate food consumption. Two distinct neuronal popu-
lations that regulate feeding behavior, the orexigenic NPY/
AgRP neurons and the anorexigenic POMC/CART neurons,
are expressed in the arcuate nucleus of the hypothalamus.
Therefore, we examined the effect of FA on the expression of
orexigenic and anorexigenic genes using the N1 hypothalamic
cell line.41 Surprisingly, FA treatment signiﬁcantly reduced the
expression of AgRP and NPY (Figure 4a and b), with no
signiﬁcant change in the expression of POMC and CART
(Figure 4c and d). Next, we examined the promoter activity of
AgRP, NPY, and POMC via luciferase assay after FA treatment.
Although there was no observable effect on POMC, FA
markedly reduced the transcriptional activity of AgRP and
NPY (Figure 4e–g). It has been reported that FoxO1 stimulates
the expression of the orexigenic neuropeptides AgRP and NPY
in the hypothalamus and that phosphorylation of FoxO1
promotes its nuclear export and hence inhibits the expression
of orexigenic neuropeptides.18,19,42 Having observed that
FoxO1 was involved in the regulation of gluconeogenic genes
in FA-treated mice (Figures 2 and 3), we investigated the dose-
dependent effect of FA on FoxO1 activity in hypothalamic cells.
As shown in Figure 4h, FA signiﬁcantly inhibited FoxO1. To
further conﬁrm the effect of FA on the expression of orexigenic
and anorexigenic neuropeptides, we isolated hypothalamic
RNA from vehicle and FA-treated mice and assayed gene
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Figure 2 Effect of FA on the expression of hepatic gluconeogenic genes. Effect of FA on expression of PEPCK (a) and G6P (b) in HepG2
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expression using Q-PCR. The FA treated mice showed a
signiﬁcant reduction in both AgRP and NYP (Figure 4i
and j) with no observable change in POMC and CART
(Figure 4k and l). These results suggest that FA might suppress
food consumption by regulating the expression and activity of
orexigenic neuropeptides in the hypothalamus through inacti-
vation of FoxO1.
DISCUSSION
Phytochemicals are natural compounds derived from plant and
marine algae extracts that have emerged as important nutra-
ceuticals and supplementary treatments in the ﬁght against
obesity and type II diabetes.30,43,44 In this study, we explored
the molecular mechanisms mediating the beneﬁcial metabolic
effects of FA using a HFD-induced obese mouse model and
in vitro analyses. We report that FA suppressed energy
consumption by inhibiting the expression and transcriptional
activity of orexigenic genes. FA also contributed to improved
insulin sensitivity by suppressing hepatic glucose production.
Further, we show that this FA-induced reduction in food intake
and suppression of hepatic glucose production was accompa-
nied by an overall improvement in whole-body energy home-
ostasis characterized by increased insulin sensitivity, glucose
tolerance, and reduced fat droplet accumulation in the liver,
especially under the HFD condition. Treatment with FA
inactivated the transcription factor FoxO1, which is known
to regulate the expression of orexigenic peptides in the
hypothalamus and gluconeogenic genes in the liver. We there-
fore suggest inactivation of FoxO1 by FA treatment as a
common molecular mechanism through which FA exerts its
beneﬁcial metabolic effects by suppressing the expression of
orexigenic and gluconeogenic genes. Further, it would be
interesting to investigate whether FA also exerts beneﬁcial
metabolic effect in normal chow-fed animals by regulating
similar mechanisms observed in HFD condition.
Obesity occurs as a result of an imbalance between energy
consumption and energy expenditure.45 In the current study,
the FA-treated mice showed resistance to HFD-induced weight
gain associated with reduced food intake compared with the
vehicle-treated littermates (Figure 1a–c). As the hypothalamus
has an important role in regulating energy intake,3,4 we
investigated whether FA is involved in the regulation of feeding
behavior in the hypothalamus. Interestingly, our results show
that FA suppressed orexigenic NPY and AgRP expression with
no signiﬁcant effect on the anorexigenic peptides POMC and
CART. The orexigenic and anorexigenic neurons regulate
feeding behavior by integrating peripheral and central stimuli,
including neurotransmitters and hormones. For example, the
satiety hormone leptin is known to exert its anorexigenic effects
by stimulating POMC neurons and inhibiting AgRP and NPY
neurons, whereas ghrelin, an orexigenic hormone produced in
the gut, is known to suppress POMC neurons and stimulate
AgRP and NPY neurons.46 Whereas the suppression of
orexigenic neurons is not always accompanied by the activation
of anorexigenic neurons, and vice versa, it would be interesting
to further investigate why the FA-induced suppression of
orexigenic genes was not accompanied by a signiﬁcant change
in anorexigenic genes by focusing on the effect of FA on energy
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expenditure and the expression of the melanocortin receptors
that mediate the anorexigenic effects of POMC. In addition,
previous reports have indicated that suppression of AgRP and
NPY is accompanied by the activation of the sympathetic tone
important for energy expenditure regulation.47–50 Therefore,
future studies should examine whether FA has a role in the
regulation of the sympathetic nervous system or energy
expenditure.
Excessive hepatic glucose production has been associated
with obesity as well as the development of type II diabetes.36 In
this study, we found that FA markedly blunted the HFD-
induced increase in PEPCK and G6P and suppressed hepatic
glucose production, leading to improved hepatic glucose
homeostasis (Figure 2). In addition, GTT and ITT tests showed
that FA improved glucose tolerance and insulin sensitivity
under HFD condition and that this was accompanied by a
signiﬁcant reduction in serum insulin and leptin levels
(Figure 1). The expression of the gluconeogenic genes PEPCK
and G6P is tightly regulated by the transcription factor FoxO1;
functional inhibition of FoxO1 was reported to reduce hepatic
gluconeogenic activity.51–53 We found that FA treatment
strongly induced phosphorylation of FoxO1 and that this
phosphorylation led to the nuclear exclusion and subsequent
reduced activity of FoxO1 on PEPCK and G6P, resulting in
improved hepatic glucose homeostasis by decreasing HFD-
induced hepatic glucose production. In addition to FoxO1, it
has been shown that cAMP response element binding (CREB)
is a critical factor that modulates hepatic glucose production
through direct regulation of PEPCK and G6P.54 The transcrip-
tional activity of FoxO1 and CREB is modulated by transcrip-
tional co-activators, including CREB-binding protein/p300,
CREB-regulated transcription co-activator 2, and peroxisome
proliferator-activated receptor gamma co-activator 1 alpha.54
Therefore, whether FA has a role in the regulation of CREB-
mediated hepatic glucose homeostasis or facilitates the inter-
action between FoxO1 and CREB, with the associated tran-
scriptional co-activators remains to be investigated.
In this study, we observed the phosphorylation and nuclear
exclusion of FoxO1 by FA. FoxO1 is regulated by various
factors that modulate its subcellular localization, DNA-binding,
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transcriptional activity and even its protein expression levels.
This is achieved mainly through post-translational modiﬁca-
tions, including phosphorylation, acetylation and ubiquitina-
tion. The serine/threonine kinase AKT is one of the major
kinases known to phosphorylate and facilitate the cytoplasmic
localization of FoxO1.55 Our studies show that FA induced the
phosphorylation of AKT with the subsequent phosphorylation
of FoxO1. Although AKT seems to be primarily involved in
phosphorylation of FoxO1, we currently do not know the exact
upstream kinases that led to FA-induced FoxO1 phosphoryla-
tion. Therefore, it would be interesting to conduct further
studies to elucidate the mechanism by which FA induces the
phosphorylation of FoxO1. As leptin and insulin regulate
energy homeostasis by converging at the PI3K/AKT/FoxO1
pathway, it would also be of great interest to examine whether
FA has potentiating or synergist effects on the metabolic
activities of insulin and leptin.
In conclusion, our study corroborates the beneﬁcial meta-
bolic effects of FA and highlights the role of FA as an
alternative therapeutic agent in the ﬁght against metabolic
syndrome. We indicate that FA might exert its beneﬁcial
metabolic effects in the hypothalamus as well as in the
periphery by regulating energy intake and hepatic glucose
homeostasis. Further, our data suggest that FA suppresses the
expression of orexigenic genes and hepatic gluconeogenic genes
by phosphorylating and inhibiting FoxO1.
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